Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
TNBC - Triple-Negative Breast Cancer: early-phase trial registry
18 of 23 indexed TNBC - Triple-Negative Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 18 currently recruiting · #724 of 28,707 conditions by registered trial count
TNBC - Triple-Negative Breast Cancer: 23 US clinical trials tracked, 18 recruiting.
TNBC - Triple-Negative Breast Cancer is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition tnbc-triple-negative-breast-cancer
OPEN 18 | RECR 78% | LATE 0 | EARLY 18 | RANK #724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Congenital Diaphragmatic Hernia (78% recruiting · 23 trials)
TNBC - Triple-Negative Breast Cancer lists 18 open slots (78% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for TNBC - Triple-Negative Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
TNBC - Triple-Negative Breast Cancer is recruiting above its size-band peers.
18 of 23 indexed trials (78.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of TNBC - Triple-Negative Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 2 of 23 trials (8.7%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical TNBC - Triple-Negative Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 23 trials that report a genuine target (sentinel values excluded). 12 of those (52.2%) plan for fewer than 100 participants.
-
TNBC - Triple-Negative Breast Cancer research is mostly interventional.
19 interventional and 4 observational studies make up this index (82.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
NCT01042379
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Elephas
NCT07327489
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Tempus AI
NCT07211178
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics
NCT05867251
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Personalis
NCT06230185
Role of the Immune Environment in Response to Therapy in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT05396612
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen
NCT05768932
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma
NCT05933265
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals
NCT06568692
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
The Methodist Hospital Research Institute
NCT05660083
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Cedars-Sinai Medical Center
NCT07017673
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04683679
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Alison Stopeck
NCT06220214
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Rima Patel
NCT06637306
NearWave Optical Molecular Monitoring
Indiana University
NCT06744465
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Memorial Sloan Kettering Cancer Center
NCT03808662
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Kari Wisinski
NCT03911973
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
George T. Budd
NCT04674306
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Stephen Shiao
NCT05491226
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on TNBC - Triple-Negative Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on TNBC - Triple-Negative Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this TNBC - Triple-Negative Breast Cancer page
23 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 TNBC - Triple-Negative Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most TNBC - Triple-Negative Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This TNBC - Triple-Negative Breast Cancer condition card totals 23 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.